Renoprotective effects and safety of sodium–glucose cotransporter 2 inhibitors in diabetic chronic kidney disease
Background: Chronic kidney disease (CKD) is a major global health burden characterized by progressive loss of renal function and high cardiovascular morbidity and mortality. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed as glucose-lowering agents, have demonstrated pleiotropic metabolic and car...